Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3061-3068

  Isaka, Masanori ^a   Komiya, Takako ^b   Takahashi, Motohide ^b   Yasuda, Yoko ^a   Taniguchi, Tooru ^a   Zhao, Yanqiu ^a   Matano, Keiko ^a   Matsui, Hideyuki ^a   Maeyama, Jun Ichi ^b   Morokuma, Kazunori ^c   Ohkuma, Kunio ^c   Goto, Norihisa ^b   Tochikubo, Kunio ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Diphtheria and tetanus antitoxin antibodies; DPT combination vaccine; Intranasal administration; Recombinant cholera toxin B subunit (rCTB)

Indexed keywords

CHOLERA TOXIN B SUBUNIT; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FORMALDEHYDE; HEMAGGLUTININ; TETANUS ANTIBODY; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BREVIBACILLUS BREVIS; DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; SYMPTOM; TETANY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AGGLUTINATION TESTS; ANIMALS; BORDETELLA PERTUSSIS; CALIBRATION; CELLS, CULTURED; CHOLERA TOXIN; DIPHTHERIA ANTITOXIN; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORMALDEHYDE; HEMAGGLUTININS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MICE; RECOMBINANT PROTEINS; TETANUS ANTITOXIN;

EID: 3843066751     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.019     Document Type: Article

References (53)

1. Elson C.O., Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 133:1984;2892-2897
2. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 59:1986;301-308
3. Clements J.D., Hartzog N.M., Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine. 6:1988;269-277
4. Tamura S., Samegai Y., Kurata H., Nagamine T., Aizawa C., Kurata T., et al. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine. 6:1988;409-413
5. DeHaan L., Feil I.K., Verweij W.R., Holtrop M., Hol W.G.J., Agsteribbe E., et al. Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur. J. Immunol. 28:1998;1243-1250
6. Douce G., Turcotte C., Cropley I., Roberts M., Pizza M., Domenghini M., et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as non-toxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA. 92:1995;1644-1648
7. DiTommaso A., Saletti G., Pizza M., Rappuoli R., Dougan G., Abrignani S., et al. Induction of antigen-specific antibodies in vaginal secretions by using a non-toxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64(3):1996;974-979
8. Tsuji T., Yokochi T., Kamiya H., Kawamoto Y., Miyama A., Asano Y. Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology. 90:1997;176-182
9. Yamamoto S., Kiyono H., Yamamoto M., Kurazono H., Imaoka K., Yamamoto M., et al. A non-toxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA. 94:1997;5267-5272
10. Douce G., Fontana M., Pizza M., Rappuoli R., Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65(7):1997;2821-2828
11. Tebbey P.W., Scheuer C.A., Peek J.A., Zhu D., LaPierre N.A., Green B.A., et al. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine. 18:2000;2723-2734
12. Tochikubo K., Isaka M., Yasuda Y., Kozuka S., Matano K., Miura Y., et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine. 16(2-3):1998;150-155
13. Wu H.-Y., Russell M.W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine. 16(2-3):1998;286-292
14. Verweij W.R., DeHaan L., Holtrop M., Agsteribbe E., Brands R., Van Scharrenburg G.J.M., et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile entertoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine. 16(20):1998;2069-2076
15. Ichikawa Y., Yamagata H., Tochikubo K., Udaka S. Very efficient extracellular production of cholera toxin B subunit using Bacillus brevis. FEMS Microbiol. Lett. 111(2-3):1993;219-224
16. Yasuda Y., Matano K., Asai T., Tochikubo K. Affinity purification of recombinant cholera toxin B subunit oligomer expressed in Bacillus brevis for potential human use as a mucosal adjuvant. FEMS Immunol. Med. Microbiol. 20(4):1998;311-318
17. Isaka M., Yasuda Y., Kozuka S., Miura Y., Taniguchi T., Matano K., et al. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B. Vaccine. 16(17):1998;1620-1626
18. Isaka M., Yasuda Y., Kozuka S., Taniguchi T., Matano K., Maeyama J., et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine. 18(7-8):2000;743-751
19. Isaka M., Yasuda Y., Taniguchi T., Kozuka S., Matano K., Maeyama J., et al. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine. 21(11-12):2003;1165-1173
20. Goto N., Maeyama J., Yasuda Y., Isaka M., Matano K., Kozuka S., et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine. 18(20):2000;2164-2171
21. Yasuda Y., Isaka M., Taniguchi T., Zhao Y., Matano K., Matsui H., et al. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies. Vaccine. 21(21-22):2003;2954-2963
22. Isaka M., Yasuda Y., Mizokami M., Kozuka S., Taniguchi T., Matano K., et al. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine. 19(11-12):2001;1460-1466
23. Sakaguchi M., Inouye S., Miyazawa H., Tamura S. Measurement of antigen-specific mouse IgE by a fluorometric reverse (IgE-capture) ELISA. J. Immunol. Methods. 116:1989;181-187
24. Miyamura K., Nishio S., Ito A., Murata R., Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. Part I. Studies on factors affecting the toxin and antitoxin titration. J. Biol. Stand. 2:1974;189-201
25. Anonymous. Freeze-dried tetanus antitoxin, equine. Minimum requirements for biological products. Association of Biological Manufacturers of Japan; 1986. p. 181-4.
26. Finney DJ. Statistical method in biological assay. 2nd ed. London: Charles Griffin; 1964.
27. Anonymous. Probit analysis. Manual of laboratory methods. Vaccine supply and quality. Geneva: WHO; 1997. p. 183-90.
28. Morokuma K. Speedy and simple determination of diphtheria and tetanus antitoxin titres by particle agglutination method. Sci. Rep. Chemo-Sero-Therap. Res. Inst. 6:1997;63-66. (in Japanese)
29. Fulthorpe A.J. Tetanus antitoxin titration by hemagglutination. J. Hyg. Camb. 55:1957;382-401
30. Sato H., Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect. Immun. 46(2):1984;415-421
31. Isaka M., Yasuda Y., Taniguchi T., Kozuka S., Matano K., Maeyama J., et al. Comparison of systemic and mucosal responses of mice to aluminium-adsorbed diphtheria toxoid between intranasal administration and subcutaneous injection. Nagoya Med. J. 45(1):2001;5-15
32. Nagai T., Suzuki Y., Kiyohara H., Susa E., Kato T., Nagamine T., et al. Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines. Vaccine. 19(32):2001;4824-4834
33. Fubara E.S., Freter R. Source and protective function of coproantibodies in intestinal disease. Am. J. Clin. Nutr. 25:1972;1357-1363
34. McNabb P.C., Tomasi T.B. Host defense mechanisms at mucosal surfaces. Annu. Rev. Microbiol. 35:1981;477-496
35. Renegar K.B., Small P.A. Jr. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 146:1991;1972-1978
36. Michetti P., Mahan M.J., Slauch J.M., Mekalanos J.J., Neutra M.R. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect. Immun. 60:1992;1786-1792
37. Marcotte H., Lavoie M.C. Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol. Mol. Biol. Rev. 62(1):1998;71-109
38. Williams R.C., Gibbons R.J. Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal. Science. 177:1972;697-699
39. Stokes C.R., Soothill J.F., Turner M.W. Immune exclusion is a function of IgA. Nature (London). 255:1975;745-746
40. Svanborg-Eden C., Svennerholm A.M. Secretory immunoglobulin A and G antibodies prevent adhesion of Escherichia coli to human urinary epitherial cells. Infect. Immun. 22:1978;790-797
41. Tratmont E.C., Ciak J., Boslego J., McChesney D.G., Brington C.C., Zollinger W. Antigenic specificity of antibodies in vaginal secretions during infection with Neisseria gonorrhoae. J. Infect. Dis. 142:1980;23-31
42. Kurono Y., Fujiyoshi T., Mogi G. Secretory IgA and bacterial adherence to nasal mucosal cells. Ann. Otol. Rhinol. Laryngol. 98:1989;273-278
43. Wold A.E., Mestecky J., Tomana M., Kobata A., Ohbayashi H., Endo T., et al. Secretory immunoglobulin A carries oligosaccharide receptors for Escherichia coli type 1 fimbrial lectin. Infect. Immun. 58:1990;3073-3077
44. Majumdar A.S., Ghose A.C. Evaluation of the biological properties of different classes of human antibodies in relation to cholera. Infect. Immun. 32:1981;9-14
45. Johnson S., Sypura W.D., Gerding D.N., Ewing S.L., Janoff E.N. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect. Immun. 63(8):1995;3166-3173
46. Mbawuike I.N., Pacheco S., Acuna C.L., Switzer K.C., Zhang Y., Harriman G.R. Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J. Immunol. 162:1999;2530-2537
47. Balmelli C., Roden R., Potts A., Schiller J., DeGrandi P., Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol. 72(10):1998;8220-8229
48. Eyles J.E., Williamson E.D., Alpar H.O. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. Int. J. Pharm. 189(1):1999;75-79
49. Saunders N.B., Shoemaker D.R., Brandt B.L., Moran E.E., Larsen T., Zollinger W.D. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect. Immun. 67(1):1999;113-119
50. Pickett T.E., Pasetti M.F., Galen J.E., Sztein M.B., Levine M.M. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar typhi strains as live mucosal vaccines and as live vectors. Infect. Immun. 68(1):2000;205-213
51. Berstad A.K., Andersen S.R., Dalseg R., Dromtorp S., Holst J., Namork E., et al. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine. 18(18):2000;1910-1919
52. Visweswaraiah A., Novotny L.A., Hjemdahl-Monsen E.J., Bakaletz L.O., Thanavala Y. Tracking the tissue distribution of maker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention. Vaccine. 20(25-26):2002;3209-3220
53. Lang D. Safety evaluation of toxin adjuvants delivered intranasally. http://www.niaid.nih.gov/dmid/enteric/intranasl.htm.